PMID- 26473281
OWN - NLM
STAT- MEDLINE
DCOM- 20170504
LR  - 20181202
IS  - 1439-7609 (Electronic)
IS  - 1439-7595 (Linking)
VI  - 26
IP  - 4
DP  - 2016 Jul
TI  - The efficacy of abatacept in Japanese patients with rheumatoid arthritis: 104 
      weeks radiographic and clinical results in clinical practice.
PG  - 499-506
LID - 10.3109/14397595.2015.1109578 [doi]
AB  - OBJECTIVE: We aimed to assess the efficacy of abatacept in Japanese patients with 
      rheumatoid arthritis (RA) in clinical practice. METHODS: We examined 92 patients 
      who received abatacept for 104 weeks. Analysis of radiographic efficacy was 
      conducted using van der Heijde-modified total Sharp score (mTSS). Disease 
      activity score was assessed using disease activity score in 28 joints (DAS28) and 
      simplified disease activity index (SDAI) by last observation carried forward. 
      RESULTS: The change in mTSS was 0.61 at 52 weeks and 0.27 at 52-104 weeks. 
      Structural remission occurred in 64.9% at 52 weeks and 76.6% at 104 weeks. The 
      significant risk factors for joint damage progression at 52 weeks were 
      prednisolone use, baseline C-reactive protein level (CRP), and erythrocyte 
      sedimentation rate (ESR), as well as average DAS28-CRP and DAS28-ESR scores, 
      SDAI, CRP, ESR, and matrix metalloproteinase-3 (MMP-3) levels. The clinical 
      remission rates were 47.8% by DAS28-CRP, 39.1% by DAS28-ESR, and 30.4% by SDAI at 
      52 weeks, were 59.8% by DAS28-CRP, 48.9% by DAS28-ESR, and 43.5% by SDAI at 104 
      weeks. CONCLUSION: This study suggested efficacy of abatacept treatment in 
      Japanese patient with RA for 104 weeks in daily clinical practice. Abatacept lead 
      to suppress joint destruction for 104 weeks.
FAU - Mochizuki, Takeshi
AU  - Mochizuki T
AD  - a Department of Orthopedic Surgery , Kamagaya General Hospital , Kamagaya , Japan 
      .
FAU - Yano, Koichiro
AU  - Yano K
AD  - b Institute of Rheumatology, Tokyo Women's Medical University , Tokyo , Japan , 
      and.
FAU - Ikari, Katsunori
AU  - Ikari K
AD  - b Institute of Rheumatology, Tokyo Women's Medical University , Tokyo , Japan , 
      and.
FAU - Hiroshima, Ryo
AU  - Hiroshima R
AD  - a Department of Orthopedic Surgery , Kamagaya General Hospital , Kamagaya , Japan 
      .
FAU - Takaoka, Hiromitsu
AU  - Takaoka H
AD  - a Department of Orthopedic Surgery , Kamagaya General Hospital , Kamagaya , Japan 
      .
FAU - Kawakami, Kosei
AU  - Kawakami K
AD  - a Department of Orthopedic Surgery , Kamagaya General Hospital , Kamagaya , Japan 
      .
FAU - Koenuma, Naoko
AU  - Koenuma N
AD  - a Department of Orthopedic Surgery , Kamagaya General Hospital , Kamagaya , Japan 
      .
FAU - Shirahata, Toshikatsu
AU  - Shirahata T
AD  - c Department of Orthopedic Surgery , Chibanishi General Hospital , Chiba , Japan.
FAU - Momohara, Shigeki
AU  - Momohara S
AD  - b Institute of Rheumatology, Tokyo Women's Medical University , Tokyo , Japan , 
      and.
LA  - eng
PT  - Journal Article
DEP - 20151223
PL  - England
TA  - Mod Rheumatol
JT  - Modern rheumatology
JID - 100959226
RN  - 0 (Antirheumatic Agents)
RN  - 7D0YB67S97 (Abatacept)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - EC 3.4.24.17 (MMP3 protein, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Abatacept/*therapeutic use
MH  - Aged
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/blood/diagnostic imaging/*drug therapy
MH  - Blood Sedimentation
MH  - C-Reactive Protein/analysis
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Male
MH  - Matrix Metalloproteinase 3/blood
MH  - Middle Aged
MH  - Remission Induction
MH  - Severity of Illness Index
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Abatacept
OT  - Modified total sharp score
OT  - Rheumatoid arthritis
OT  - Structural remission
EDAT- 2015/10/17 06:00
MHDA- 2017/05/05 06:00
CRDT- 2015/10/17 06:00
PHST- 2015/10/17 06:00 [entrez]
PHST- 2015/10/17 06:00 [pubmed]
PHST- 2017/05/05 06:00 [medline]
AID - 10.3109/14397595.2015.1109578 [doi]
PST - ppublish
SO  - Mod Rheumatol. 2016 Jul;26(4):499-506. doi: 10.3109/14397595.2015.1109578. Epub 
      2015 Dec 23.